Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals, now part of Viatris Inc., focuses on developing and commercializing innovative therapies for ophthalmic diseases, including the FDA-approved Tyrvaya nasal spray for dry eye disease.
Company Overview
Oyster Point Pharmaceuticals, now a part of Viatris Inc., focuses on the discovery, development, and commercialization of first-in-class therapies to treat ophthalmic disease. The company is headquartered at 202 Carnegie Center, Suite 106, Princeton, NJ 08540.
FDA Approved Products
Oyster Point Pharmaceuticals' first commercial product, Tyrvaya (varenicline solution) nasal spray, was approved in 2021. This product is FDA approved for the treatment of dry eye disease.
Innovative Gene Therapy Approaches
Oyster Point Pharmaceuticals is developing a proprietary Enriched Tear Film (ETF™) Gene Therapy platform for the treatment of select ocular surface diseases. Their investigational ETF™ Gene Therapy approach uses adeno-associated virus (AAV) vectors to deliver target genes to cells. In preclinical models, this approach has shown that the protein-producing machinery in the lacrimal gland can be harnessed to secrete selected proteins, peptides, and enzymes in the body's natural tear film.
Research Collaborations
Oyster Point Pharmaceuticals has partnered in a research collaboration to develop unique therapies to treat bacterial infections in ophthalmology using bacteriophages. This collaboration aims to harness the power of bacteriophages to target bacterial infections specifically.
Product Pipeline
Oyster Point Pharmaceuticals' product pipeline includes several investigational therapies. These include OC-01 (varenicline solution) nasal spray for neurotrophic keratopathy and dry eye associated with contact lens intolerance, OC-101 (AAV-NGF) for neurotrophic keratopathy, and OC-103 (AAV-DAO) for vernal keratoconjunctivitis and atopic keratoconjunctivitis. Additionally, OC-01 nasal spray is being explored for other applications such as ocular surface preparation for refractive surgeries.